In brief
- A phase 1/2 trial of vaporized 5-MeO-DMT (formulation GH001) in patients with treatment-resistant depression was published in Frontiers in Psychiatry in 2023.
- Using an individualized dosing regimen, 7 out of 8 patients (87.5%) achieved remission of depressive symptoms by day 7, with many experiencing relief within hours.
- These are promising but highly preliminary results: the sample size is tiny, the design was open-label without a placebo, and administration occurred in a controlled clinical setting. They do not yet prove a “cure.”
5-MeO-DMT is a fast-acting, intense psychedelic tryptamine that exists in nature and can be synthesized in a laboratory. In recent years, it has entered the realm of formal clinical research as a potential treatment for depression that does not respond to standard medications. The first published data point to a rapid and remarkable antidepressant effect, although the research is still in a very early stage.
The study
The reference study was authored by Reckweg et al. and published in 2023 in the journal Frontiers in Psychiatry. It was a phase 1/2, open-label (no placebo group) trial conducted at a single center with patients diagnosed with treatment-resistant depression. The substance was a synthetic 5-MeO-DMT formulation called GH001, administered via vapor inhalation using a standardized medical device. Phase 1 evaluated single doses of 12 mg and 18 mg in 8 people; phase 2 tested an individualized dosing regimen (up to three escalating doses of 6, 12, and 18 mg in a single session) in another 8. In total, there were 16 participants. The primary goal of phase 2 was to measure how many achieved remission—a score of 10 or less on the MADRS scale, the standard tool for quantifying depression severity—by day 7.
What was found
In the individualized dosing group, 7 of the 8 patients (87.5%) were in remission by day 7, with an average reduction in MADRS scores of 24.4 points, or about 76% from baseline (p<0.0001). The speed of the effect is striking: six of those remissions occurred within two hours of administration, and all had been achieved by the first day. In the single-dose phase 1 groups, the percentages were lower—50% remission with 12 mg and 25% with 18 mg—suggesting that the strategy of escalating the dose within the same session might be more effective than a single administration. Regarding safety, the authors describe the inhalation as "well-tolerated": there were no serious adverse events, and reactions were mild to moderate, primarily headache, anxiety, nausea, and occasional episodes of flashbacks. No cognitive impairment or relevant alterations in vital signs were detected.
What it means (and what it doesn’t)
An honest reading requires looking in both directions. On one hand, such high and rapid remission figures in people who no longer responded to conventional treatments are simply rare in psychiatry; they align with the signals other teams are seeing with psychedelics and with the pharmacology of 5-MeO-DMT itself, which has a very brief but highly potent effect. On the other hand, it is best not to get carried away by enthusiasm. This is a trial with 16 people in total and only 8 in the group that provided the headline data: a tiny sample. As an open-label study without a placebo, the weight of expectations and the placebo effect—especially marked in depression—cannot be ruled out. Everything took place in a careful clinical context, with professional preparation and support, very far from self-administration. And the follow-up was short: knowing how long the improvement lasts requires longer studies.
None of this justifies speaking of a “miracle” or a “cure,” just as it does not justify reflexive rejection of a molecule that science is beginning to study in earnest. The reasonable path is the one already taken by several groups: larger, randomized, placebo-controlled phase 2 and 3 trials that confirm or correct these early signals. Regarding legal status, it is worth remembering as an objective fact that 5-MeO-DMT is controlled in most countries and its use today is limited to authorized research; its eventual arrival in clinical practice will depend on whether those larger trials support what these initial data merely hint at.
Source
- Reckweg JT, van Leeuwen CJ, Henquet C, et al. A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Frontiers in Psychiatry, 2023. DOI: 10.3389/fpsyt.2023.1133414
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
